Table 1.

Clinical characteristics and outcomes of CLL patients with venetoclax resistance after BTK-inhibitor treatment

Pt no.	Sex	No. of prior therapies	IgVH status	Complex karyotype*	MYC	Tris12	del13q	ATM	p53	Age at venetoclax initiation, y	Months on venetoclax	Progression type	Survival after progression, mo
1	M	4	Unmutated	Yes	Yes		Yes		Yes	74	25	CLL type	NA
2	M	13	Unmutated	No				Yes		53	22	CLL type	NA
3	M	2	Unmutated	Yes			Yes	Yes		66	24	CLL type	NA
4	M	7	Unmutated	Yes			Yes		Yes	69	24	CLL type	NA
5	M	5	Unmutated	Yes						57	13	CLL type	6
6	M	6	Unmutated	Yes					Yes	79	22	CLL type	10
7†	M	5	Unmutated	Yes	Yes	Yes			Yes	59	2	CLL type	NA
8	M	8	Unmutated	Yes			Yes			72	33	CLL type	NA
9	F	6	Unmutated	Yes			Yes		Yes	59	19	Richter	2
10	M	6	Unmutated	Yes					Yes	55	6	Richter	2
11	F	8	Mutated	Yes	Yes	Yes	Yes	Yes	Yes	65	4	Richter	17

ATM, ataxia telangectasia mutation; F, female; IgVH, mutation status of the immunoglobulin heavy chain variable region; M, male; NA, not applicable; Pt no., patient number.

^*Defined as ≥3 abnormalities on CpG oligonucleotide-stimulated karyotype.

^†Patient also received acalabrutinib prior to venetoclax.